Related Experiment Video
Updated: Jun 15, 2025
05:58
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
126
Diabetic cardiomyopathy: Emerging therapeutic options
Cornelius James Fernandez1, Sahana Shetty2, Joseph M Pappachan3,4,5
1Department of Endocrinology & Metabolism, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston PE21 9QS, United Kingdom.
World Journal of Diabetes
|August 28, 2024
Summary
Diabetic cardiomyopathy (DbCM) is a complication of diabetes mellitus (DM) that affects heart function. A new study explores teneligliptin
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetic cardiomyopathy (DbCM) is an underrecognized complication of diabetes mellitus (DM).
- Early stages involve diastolic dysfunction, progressing to heart failure with preserved or reduced ejection fraction.
- Mechanisms and management of DbCM remain incompletely understood compared to other diabetes-related cardiac issues.
Discussion:
- A recent study investigated pathophysiological alterations and the therapeutic potential of teneligliptin in diabetic mouse models of DbCM.
- This research may offer insights into potential new management strategies for DbCM.
- Translating findings from animal models to human clinical practice requires careful consideration due to potential pathobiological differences.
Key Insights:
- Teneligliptin shows potential as a therapeutic agent in experimental models of diabetic cardiomyopathy.
- Understanding DbCM requires further investigation into its complex pathophysiological mechanisms.
- Prompt management of DM, hypertension, and dyslipidemia is crucial for patients with DbCM.
Outlook:
- Experimental studies like this encourage further research into effective treatments for diabetic cardiomyopathy.
- Future research should focus on validating findings in human clinical trials.
- Developing targeted therapies for DbCM is essential for improving patient outcomes.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:15Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
421
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
421
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149